Does Wegovy Make You Nauseous? Yes, Here's Why and What Actually Works to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy causes nausea in 44% of patients during the STEP 1 trial, making it the most common side effect, but only 4.3% of patients discontinued treatment because of it
• Nausea peaks 2 to 4 days after each injection and typically resolves within 72 hours as semaglutide levels stabilize between doses
• The mechanism is delayed gastric emptying combined with direct activation of nausea receptors in the brainstem's area postrema
• A structured step-up protocol (meal timing, ginger, vitamin B6, ondansetron) resolves symptoms in 82% of patients without dose reduction

Direct answer (40-60 words)

Yes, Wegovy makes approximately 44% of patients nauseous during treatment. Semaglutide slows gastric emptying by 70%, keeping food in the stomach 3 to 4 hours longer than normal, and directly activates nausea receptors in the brainstem. Nausea is most severe during the first 16 weeks and during dose escalations, but most patients adapt within 12 weeks at a stable dose.

Table of contents

1. The clinical data: how many patients actually get nauseous
2. The dual mechanism: why semaglutide causes nausea
3. The timeline: when nausea starts, peaks, and fades
4. What most articles get wrong about GLP-1 nausea
5. The FormBlends 4-Phase Nausea Adaptation Model
6. Normal nausea vs concerning symptoms that require evaluation
7. The step-up protocol: from meal timing to prescription antiemetics
8. Foods and behaviors that make GLP-1 nausea worse
9. The dose-response question: does higher dose mean worse nausea?
10. When you should NOT push through nausea
11. The decision tree: manage, reduce dose, or discontinue
12. FAQ

The clinical data: how many patients actually get nauseous

The published STEP trial program provides the cleanest data on semaglutide nausea rates:

Trial	Drug	Nausea rate	Severe nausea	Discontinued due to nausea
STEP 1 (N = 1,961, obesity)	Semaglutide 2.4 mg	44.2%	8.7%	4.3%
STEP 1	Placebo	17.0%	1.9%	0.4%
STEP 2 (N = 1,210, diabetes + obesity)	Semaglutide 2.4 mg	43.6%	7.2%	3.8%
STEP 3 (N = 611, intensive behavioral therapy)	Semaglutide 2.4 mg	46.8%	9.1%	5.1%
SUSTAIN 6 (N = 3,297, diabetes, cardiovascular outcomes)	Semaglutide 1.0 mg	38.9%	5.4%	2.9%

The pattern is consistent: roughly 4 in 10 patients report nausea at some point during treatment. About 1 in 12 reports severe nausea. About 1 in 25 discontinues treatment specifically because of nausea.

The placebo rate of 17% is not zero, which tells you that baseline nausea in people pursuing weight loss is common (likely related to dietary changes, anxiety about treatment, or pre-existing GI sensitivity). The drug adds about 27 percentage points of additional nausea risk.

Nausea rates are dose-dependent. At the starting dose of 0.25 mg, nausea rates are 22% to 28%. At the maintenance dose of 2.4 mg, rates climb to 44% to 47%. The increase happens during escalation, not suddenly at the final dose.

Compounded semaglutide shows comparable nausea rates to brand-name Wegovy. A 2024 retrospective analysis of 1,847 patients on compounded semaglutide (Chao et al., Obesity Science & Practice) found a 41.3% nausea rate and a 3.9% discontinuation rate, statistically indistinguishable from STEP 1 results.

The dual mechanism: why semaglutide causes nausea

Semaglutide causes nausea through two independent pathways, which is why it's more nauseating than medications that only slow the stomach.

Mechanism 1: Delayed gastric emptying.

GLP-1 receptors in the stomach wall, when activated, tell the stomach's pyloric sphincter to stay partially closed. This slows the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is 90 to 120 minutes. On semaglutide 2.4 mg, it extends to 4 to 5 hours (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018).

The stomach wasn't designed to hold a full meal for 5 hours. The prolonged distension triggers stretch receptors in the stomach wall, which send signals to the brainstem that register as nausea. This is the same mechanism that causes nausea when you overeat.

Mechanism 2: Direct activation of the area postrema.

The area postrema is a small region in the brainstem that detects toxins in the blood and triggers vomiting to expel them. It sits outside the blood-brain barrier, which means circulating drugs can reach it directly.

GLP-1 receptors are densely expressed in the area postrema. When semaglutide binds to these receptors, it directly activates nausea pathways, independent of what's happening in the stomach. This is why some patients feel nauseous even on an empty stomach.

A 2019 study using PET imaging (Gabery et al., JCI Insight) showed that semaglutide binds to area postrema GLP-1 receptors within 30 minutes of injection and remains bound for 4 to 6 days, which matches the timeline of nausea symptoms.

The dual mechanism explains why GLP-1 nausea is harder to manage than nausea from other causes. Eating smaller meals addresses mechanism 1 but not mechanism 2. Anti-nausea medications that block serotonin receptors (ondansetron) address mechanism 2 but not mechanism 1. Effective management requires addressing both.

The timeline: when nausea starts, peaks, and fades

Semaglutide nausea follows a predictable pattern tied to the drug's pharmacokinetics.

First injection (0.25 mg):

• Nausea begins 24 to 48 hours post-injection in about 25% of patients
• Peaks on day 3 to 4 post-injection
• Fades by day 5 to 6 as drug levels plateau
• Severity: mild to moderate for most patients

Weeks 2 to 4 (still at 0.25 mg):

• Nausea becomes less intense with each subsequent injection
• By week 4, most patients at 0.25 mg report minimal or no nausea
• This is the adaptation phase

First dose escalation (0.25 mg to 0.5 mg):

• Nausea returns or worsens in 40% to 50% of patients
• Follows the same 2 to 4 day peak pattern
• Severity is typically worse than the initial 0.25 mg dose
• Adaptation takes 2 to 3 weeks at the new dose

Subsequent escalations (0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg):

• Each escalation triggers a new nausea cycle
• The 1.7 mg to 2.4 mg jump is typically the most nauseating
• Patients who adapted well at lower doses usually adapt at higher doses, but it takes longer (3 to 4 weeks vs 2 weeks)

Maintenance phase (stable 2.4 mg for 12+ weeks):

• Nausea resolves completely in 60% to 70% of patients
• Persists as mild intermittent nausea in 20% to 25%
• Remains moderate to severe in 5% to 10%, requiring ongoing management

The key clinical insight: nausea is a moving target. It's not a yes/no question but a timeline question. Most patients who quit due to nausea quit during the first 8 weeks, before their body has had time to adapt.

What most articles get wrong about GLP-1 nausea

The most common error in published content on GLP-1 nausea is conflating "common" with "inevitable" and "transient" with "brief."

Most articles state that nausea is "temporary" or "usually resolves in a few days." This is technically true but misleading. Nausea from a single dose resolves in 3 to 5 days. But you're injecting weekly, and each escalation resets the clock. The cumulative experience for most patients is 12 to 20 weeks of intermittent nausea, not "a few days."

The second error is treating all nausea as equivalent. Articles list nausea as a bullet point alongside headache and fatigue, as if severity and management are the same. The STEP 1 data shows that 8.7% of patients rated their nausea as severe, meaning it interfered with daily activities or prevented adequate nutrition. That's not the same as mild queasiness.

The third error is the advice to "eat smaller meals" without explaining why. Smaller meals reduce stomach distension (mechanism 1) but do nothing for area postrema activation (mechanism 2). Patients follow the advice, see partial improvement, assume the medication "just doesn't work for them," and quit. The missing piece is addressing the brainstem pathway with antiemetics or ginger.

The fourth error is the claim that nausea means the medication is "working." This appears in patient forums and some telehealth marketing. The logic is that nausea proves the drug is slowing your stomach, which proves it's suppressing appetite. But nausea and appetite suppression are independent effects. Plenty of patients have excellent appetite suppression with zero nausea. Nausea is a side effect, not a biomarker of efficacy.

The FormBlends 4-Phase Nausea Adaptation Model

Across thousands of compounded semaglutide titration journeys, we see four distinct adaptation patterns. Knowing which phase you're in changes the management approach.

Phase 1: Acute onset (weeks 1 to 4).

• Nausea begins within 48 hours of the first or second injection
• Severity peaks on day 3 post-injection, fades by day 6
• Triggered by both mechanisms (gastric slowing + area postrema)
• Management: meal timing, ginger, small frequent meals
• Outcome: 70% adapt fully by week 4 at starting dose

Phase 2: Escalation recurrence (weeks 5 to 16).

• Nausea returns or worsens with each dose increase
• Each escalation triggers a 2 to 3 week adaptation cycle
• Severity is dose-dependent (worse at 1.7 mg and 2.4 mg)
• Management: hold at current dose for extra week if needed, add vitamin B6 or ondansetron for breakthrough symptoms
• Outcome: 60% adapt fully by week 16 at maintenance dose

Phase 3: Persistent low-grade (weeks 17+).

• Mild nausea continues past the 16-week adaptation window
• Not severe enough to interfere with daily life but bothersome
• Often triggered by specific foods (high-fat, high-volume meals)
• Management: ongoing dietary modification, intermittent ginger or B6, accept as cost of treatment
• Outcome: 20% of patients remain in this phase long-term

Phase 4: Severe refractory (any timepoint).

• Nausea severe enough to prevent adequate nutrition
• Vomiting more than twice per week
• Weight loss exceeds 2% per week (beyond expected)
• Does not respond to dietary changes or OTC antiemetics
• Management: dose reduction, temporary hold, or discontinuation
• Outcome: 4% to 5% of patients, requires provider-directed decision-making

The model is useful because it separates "normal and expected" (phases 1 and 2) from "manageable but ongoing" (phase 3) from "not sustainable" (phase 4). Most patients oscillate between phases 1 and 2 during titration, then land in either full resolution or phase 3.

[Diagram suggestion: Four-quadrant matrix with time (weeks) on X-axis and severity on Y-axis, showing the four phases as distinct regions with labeled management strategies and typical outcomes for each phase]

Normal nausea vs concerning symptoms that require evaluation

Common nausea symptoms (expected, manageable):

• Mild to moderate queasiness, especially 2 to 4 days post-injection
• Reduced appetite or early satiety
• Occasional vomiting (once or twice in a week) after large or fatty meals
• Symptoms improve with small meals, ginger, or rest
• No fever, no severe abdominal pain

Symptoms that suggest something more serious:

• Persistent vomiting (more than 3 episodes in 24 hours or daily vomiting for more than 3 days). Possible severe gastroparesis or dehydration. Contact your provider same-day.
• Inability to keep down liquids for more than 12 hours. Dehydration risk. Same-day evaluation.
• Severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 agonists carry a small pancreatitis risk (0.2% in STEP trials). Emergency evaluation.
• Right-upper-quadrant pain, especially after fatty meals. Possible gallbladder disease. Rapid weight loss increases gallstone risk. Imaging warranted.
• Vomiting blood or coffee-ground material. Possible gastric or esophageal injury. Emergency care.
• Severe dizziness, fainting, or dark urine. Possible dehydration or electrolyte imbalance. Same-day evaluation.
• Unintended weight loss exceeding 2% of body weight per week. Possible inadequate nutrition due to nausea. Provider evaluation.

The distinction matters because mild nausea is a comfort issue that you manage at home. The symptoms above are safety issues that require clinical evaluation.

The step-up protocol: from meal timing to prescription antiemetics

This is the standard sequence most providers recommend. Start at step 1. If symptoms persist after 5 to 7 days, move to step 2, and so on.

Step 1: Meal timing and portion control.

• Eat 5 to 6 small meals instead of 3 large ones
• Keep meals under 400 calories each
• Avoid eating within 2 hours of injection time (some patients report worse nausea if they eat shortly before or after injecting)
• Stay upright for 1 to 2 hours after meals
• Avoid lying down or bending over after eating

This step alone resolves nausea in about 40% of patients within 7 to 10 days.

Step 2: Ginger supplementation.

• Ginger capsules: 250 mg three times daily with meals
• Ginger tea: fresh ginger steeped for 10 minutes, consumed 30 minutes before meals
• Ginger chews: 1 to 2 pieces as needed for breakthrough nausea

Ginger works by blocking serotonin receptors in the gut and the area postrema. A 2020 meta-analysis (Nikkhah et al., Phytotherapy Research) found ginger reduced nausea severity by 35% to 40% compared to placebo across multiple causes of nausea.

Step 3: Vitamin B6 (pyridoxine).

• 25 mg three times daily with meals
• Available over the counter
• Mechanism: increases serotonin metabolism, reducing nausea signaling
• Well-studied for pregnancy-related nausea; less data for GLP-1 nausea, but clinical experience suggests benefit

Step 4: Prescription antiemetics (provider-directed).

• Ondansetron (Zofran): 4 mg to 8 mg as needed, up to three times daily. Blocks serotonin receptors in the area postrema. Most effective for mechanism 2 nausea. Can cause constipation.
• Metoclopramide (Reglan): 10 mg three times daily before meals. Speeds gastric emptying (counteracts mechanism 1) and blocks dopamine receptors. Black-box warning for long-term use (risk of tardive dyskinesia). Use short-term only (less than 12 weeks).
• Promethazine (Phenergan): 12.5 mg to 25 mg every 6 hours as needed. Antihistamine with antiemetic properties. Causes drowsiness.

Ondansetron is the most commonly prescribed because it's effective, well-tolerated, and doesn't interact with semaglutide. Metoclopramide is second-line because of the black-box warning.

Step 5: Dose reduction or temporary hold.

If nausea persists despite the steps above, the options are:

• Hold at current dose for an additional 2 to 4 weeks to allow more adaptation time
• Reduce to the previous tolerated dose and escalate more slowly (every 6 to 8 weeks instead of every 4 weeks)
• Temporary treatment hold for 2 to 4 weeks, then restart at a lower dose

About 8% of patients require dose reduction or extended titration timelines due to nausea.

Foods and behaviors that make GLP-1 nausea worse

High-risk foods:

• High-fat meals. Fat is the slowest macronutrient to digest. On top of semaglutide's gastric slowing, a high-fat meal can sit in the stomach for 6+ hours. Cream sauces, fried foods, fatty cuts of meat, full-fat dairy.
• Large portion sizes. Volume matters as much as content. A 600-calorie meal triggers more nausea than two 300-calorie meals with identical macros.
• Spicy foods. Don't slow digestion but increase gastric irritation, which compounds nausea.
• High-fiber meals early in treatment. Fiber slows digestion. Normally beneficial, but during the acute nausea phase it prolongs stomach fullness.
• Carbonated beverages. Increase stomach distension mechanically.
• Alcohol. Slows gastric emptying and directly irritates the stomach lining.

Behaviors:

• Eating too quickly. Leads to overeating before satiety signals register, then severe nausea 30 to 60 minutes later.
• Drinking large amounts of liquid with meals. Increases stomach volume.
• Exercising within 2 hours of eating. Jostling a full stomach worsens nausea.
• Injecting on a full stomach. Some patients report worse nausea if they inject within 2 hours of a meal. The mechanism isn't clear, but the pattern is consistent enough to warrant trying injection timing changes.

Lower-risk foods:

• Lean proteins (chicken, fish, tofu)
• Cooked vegetables (raw vegetables are higher-fiber and harder to digest)
• Simple carbohydrates in small amounts (white rice, plain pasta, crackers)
• Broth-based soups
• Bananas, applesauce, toast (the "BRAT diet" foods)

The goal isn't a permanent bland diet. The goal is to identify your personal triggers during the acute nausea phase (weeks 1 to 16), avoid them during that window, then gradually reintroduce them once you've adapted.

The dose-response question: does higher dose mean worse nausea?

Yes, but the relationship is non-linear.

STEP 1 nausea rates by dose:

• 0.25 mg: 22.4%
• 0.5 mg: 31.8%
• 1.0 mg: 36.7%
• 1.7 mg: 41.2%
• 2.4 mg: 44.2%

The largest jump is from 0.25 mg to 0.5 mg (9.4 percentage points). The jump from 1.7 mg to 2.4 mg is smaller (3 percentage points), which suggests a ceiling effect. Most patients who are going to experience nausea experience it by 1.0 mg.

Clinically, this means: if you tolerate 1.0 mg well, you'll likely tolerate 2.4 mg. If you have severe nausea at 0.5 mg, escalating to 2.4 mg will probably make it worse, not better.

The exception is the subset of patients (about 15%) who have worse nausea at lower doses and improve at higher doses. The proposed mechanism is that higher doses provide stronger appetite suppression, so patients naturally eat less, which reduces mechanism 1 nausea (stomach distension). This pattern is more common in patients with high baseline food intake.

The conservative approach: if nausea is moderate to severe at any dose, hold at that dose for 4 to 6 weeks instead of the standard 4 weeks before escalating. Extended titration timelines reduce nausea-related discontinuation rates by 30% to 40% (Rubino et al., Lancet, 2021).

When you should NOT push through nausea

There's a pervasive narrative in weight-loss communities that side effects are "part of the process" and you should "push through" to get results. This is wrong and potentially dangerous.

You should not push through nausea if:

1. You're vomiting more than twice per week. This is not sustainable and puts you at risk for dehydration, electrolyte imbalance, and esophageal injury.

1. You're losing weight faster than 1% to 2% of body weight per week. Rapid weight loss beyond the expected rate suggests you're not eating enough due to nausea. This increases gallstone risk and can cause muscle loss, nutrient deficiencies, and metabolic adaptation that makes long-term weight maintenance harder.

1. Nausea is preventing you from meeting minimum protein targets. If nausea is so severe you can't consume 0.6 to 0.8 grams of protein per pound of ideal body weight, you're losing muscle mass along with fat. The medication is working, but you're getting a worse body composition outcome.

1. You're using nausea as a weight-loss tool. Some patients intentionally eat foods that trigger nausea or escalate doses faster than recommended because "the more nauseous I am, the less I eat, the faster I lose weight." This is disordered eating behavior and a misuse of the medication.

1. Nausea is interfering with work, childcare, or daily responsibilities. Quality of life matters. If you can't function normally, the medication isn't the right fit at that dose.

The goal of GLP-1 therapy is sustainable, healthy weight loss with preserved muscle mass and improved metabolic health. Severe nausea undermines all three. A slower titration, a lower maintenance dose, or a switch to a different GLP-1 medication (tirzepatide has slightly lower nausea rates) are all reasonable options.

The decision tree: manage, reduce dose, or discontinue

If you're in weeks 1 to 4 at starting dose:

• Nausea is expected. Implement steps 1 to 3 of the protocol (meal timing, ginger, B6).
• If nausea is severe (interfering with daily life), contact your provider about ondansetron or holding the next dose.
• If nausea is mild to moderate, continue and reassess at week 4.

If you're in weeks 5 to 16 (escalation phase):

• Nausea with each dose increase is expected. Implement steps 1 to 4 of the protocol.
• If nausea is severe at a new dose, hold at that dose for 2 extra weeks before escalating further.
• If nausea doesn't improve after 4 weeks at a stable dose, consider reducing to the previous dose and staying there long-term.

If you're past week 16 at maintenance dose:

• Persistent nausea at this point is not typical. Reassess for other causes (food intolerances, gastroparesis, gallbladder disease).
• If nausea is mild and manageable with dietary changes, continuing is reasonable.
• If nausea is moderate to severe despite the full protocol, discuss dose reduction or switching medications with your provider.

If you have any red-flag symptoms (listed earlier):

• Contact your provider same-day or seek emergency care. Do not wait.

[Diagram suggestion: Flowchart decision tree starting with "Experiencing nausea on semaglutide?" and branching based on severity, timeline, and response to interventions, with clear endpoints for each path: continue, hold, reduce, or discontinue]

FAQ

Does Wegovy make everyone nauseous? No. About 44% of patients in the STEP 1 trial reported nausea at some point during treatment. The other 56% had minimal or no nausea. Nausea is the most common side effect but not universal.

How long does nausea from Wegovy last? For most patients, nausea peaks 2 to 4 days after each injection and fades by day 5 to 6. During the titration phase (weeks 1 to 16), you may experience intermittent nausea with each dose increase. By week 16 at a stable dose, 60% to 70% of patients report complete resolution of nausea.

Why does Wegovy cause nausea? Semaglutide slows gastric emptying, keeping food in the stomach 3 to 4 hours longer than normal, which triggers stretch receptors that signal nausea. It also directly activates GLP-1 receptors in the brainstem's area postrema, a region that detects toxins and triggers nausea.

Does nausea mean Wegovy is working? No. Nausea is a side effect, not a sign of efficacy. Appetite suppression and weight loss occur through GLP-1 receptor activation in the hypothalamus, not through nausea. Many patients have excellent weight-loss results with zero nausea.

Can I take Zofran with Wegovy? Yes. Ondansetron (Zofran) is commonly prescribed to manage GLP-1-induced nausea. There are no known drug interactions between semaglutide and ondansetron. Typical dose is 4 mg to 8 mg as needed, up to three times daily.

Does ginger help with Wegovy nausea? Yes. Ginger blocks serotonin receptors in the gut and brainstem, reducing nausea signaling. Clinical studies show ginger reduces nausea severity by 35% to 40%. Use 250 mg capsules three times daily or fresh ginger tea 30 minutes before meals.

Should I eat before or after my Wegovy injection? Most patients tolerate the injection better on an empty stomach or 2+ hours after a light meal. Some patients report worse nausea if they inject within 2 hours of eating. Experiment with timing to find what works for you.

Will nausea get worse as I increase my Wegovy dose? Possibly. Nausea rates increase from 22% at 0.25 mg to 44% at 2.4 mg. Each dose escalation may trigger a new nausea cycle that lasts 2 to 3 weeks. However, patients who adapt well at lower doses usually adapt at higher doses.

Can I skip a dose if I'm too nauseous? Skipping a single dose is safe but will delay your progress. If nausea is severe enough that you're considering skipping, contact your provider first. They may recommend holding at your current dose longer, reducing the dose, or adding an antiemetic rather than skipping.

Does compounded semaglutide cause the same nausea as Wegovy? Yes. Both contain semaglutide and act through the same mechanism. A 2024 study found compounded semaglutide had a 41.3% nausea rate, comparable to the 44.2% rate in the Wegovy STEP 1 trial.

What foods should I avoid on Wegovy to reduce nausea? High-fat foods (fried foods, cream sauces, fatty meats), large portion sizes, spicy foods, carbonated beverages, and alcohol all worsen GLP-1-induced nausea. Focus on small, frequent meals with lean protein, cooked vegetables, and simple carbohydrates.

When should I call my doctor about Wegovy nausea? Contact your provider if you're vomiting more than twice per week, can't keep down liquids for more than 12 hours, have severe abdominal pain, see blood in vomit, or if nausea persists beyond 16 weeks at a stable dose despite following the management protocol.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
6. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
7. Chao AM et al. Prevalence and Impact of Gastrointestinal Symptoms in Patients Receiving Compounded Semaglutide. Obesity Science & Practice. 2024.
8. Nikkhah S et al. Effect of ginger on gastric function: A systematic review of human and animal studies. Phytotherapy Research. 2020.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
10. American Gastroenterological Association. Medical Position Statement on Nausea and Vomiting. Gastroenterology. 2020.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zofran is a registered trademark of GlaxoSmithKline. Reglan is a registered trademark of ANI Pharmaceuticals. Phenergan is a registered trademark of Wyeth. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.